Pituitary hypophysial suppression in assisted human reproduction with Cetrorelix
Dolors Estrada M
Record ID 32002000815
Catalan, English, Spanish
Authors' objectives:
The objectives of this report were: 1) to evaluate the efficacy and the safety of the antagonist Cetrorelix versus the gonadotropin-releasing hormone (GnRH) agonists of controlled ovarian hyperstimulation (COH) for assisted human reproduction (AHR), and 2) the estimation of the cost of pituitary suppression per cycle of COH treatment for AHR on the basis of the consumption of GnRH analogues, according to the medicinal products currently available in Spain.
Authors' recommendations:
Although the antagonist Cetrorelix maintains premature releases of luteinizing hormone (LH) below 2% of the cycles and reduces the incidence of serious OHSS, the duration of the treatment cycle and the consumption of bottles of gonadotropin hMG per cycle, it obtains poorer clinical results than the long luteal administration protocol of the agonists. Therefore, on the strength of current data, a switch in strategy in COH programmes for AHR cannot be justified, and consequently the recommended guideline for pituitary suppression is the administration of GnRHagonists according to the long protocol.
Authors' methods:
Systematic review
Details
Project Status:
Completed
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Fertility Agents, Female
- Pituitary Hormones
- Reproductive Techniques, Assisted
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Technology Assessment and Research (CAHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.